{
    "info": {
        "nct_id": "NCT05123040",
        "official_title": "Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study",
        "inclusion_criteria": "HCT recipients over 12 years of age within the first 7 days of initial treatment of high-risk aGVHD, defined as:\n\n* Newly diagnosed Minnesota high-risk aGVHD -OR-\n* Newly diagnosed Minnesota standard risk aGVHD with plasma amphiregulin ≥ 33 pg/ml tested at the UMN Cytokine Reference Lab. For amphiregulin lab ordering information, see Fairview Lab Guide: http://labguide.fairview.org/showtest.asp?testid=6766&format=long -OR-\n* Newly diagnosed Minnesota standard risk aGVHD Ann Arbor 3 biomarkers tested by Viracor. For ordering information, see: https://www.viracor-eurofins.com/test-menu/403572p-agvhd-symptomatic- onset-algorithm/\n\n  * Renal: Serum creatinine ≤2.5x upper limit of normal (ULN)\n  * Cardiac: Left ventricular ejection fraction (LVEF) ≥ 35%\n  * Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds).\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "* Progressive malignancy\n* Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment\n* Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)\n* Unwilling or unable to stop GnRH antagonists, aromatase inhibitors, or anti-androgens\n* History of a hormone responsive malignancy\n* Current thromboembolic disease requiring full-dose anticoagulation - patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible\n* Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation status\n* Pregnancy\n* Women or men of childbearing potential unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Newly diagnosed Minnesota high-risk aGVHD -OR-",
                "criterions": [
                    {
                        "exact_snippets": "Newly diagnosed Minnesota high-risk aGVHD",
                        "criterion": "Minnesota high-risk acute graft-versus-host disease (aGVHD)",
                        "requirement": {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Newly diagnosed Minnesota high-risk aGVHD",
                        "criterion": "Minnesota high-risk acute graft-versus-host disease (aGVHD)",
                        "requirement": {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Renal: Serum creatinine ≤2.5x upper limit of normal (ULN)",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine ≤2.5x upper limit of normal (ULN)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum creatinine ≤2.5x upper limit of normal (ULN)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Newly diagnosed Minnesota standard risk aGVHD Ann Arbor 3 biomarkers tested by Viracor. For ordering information, see: https://www.viracor-eurofins.com/test-menu/403572p-agvhd-symptomatic- onset-algorithm/",
                "criterions": [
                    {
                        "exact_snippets": "Newly diagnosed",
                        "criterion": "diagnosis status",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "newly diagnosed"
                        }
                    },
                    {
                        "exact_snippets": "Minnesota standard risk aGVHD",
                        "criterion": "Minnesota standard risk aGVHD",
                        "requirement": {
                            "requirement_type": "risk category",
                            "expected_value": "standard risk"
                        }
                    },
                    {
                        "exact_snippets": "Minnesota standard risk aGVHD",
                        "criterion": "Minnesota standard risk aGVHD",
                        "requirement": {
                            "requirement_type": "disease",
                            "expected_value": "acute graft-versus-host disease (aGVHD)"
                        }
                    },
                    {
                        "exact_snippets": "Ann Arbor 3 biomarkers tested by Viracor",
                        "criterion": "Ann Arbor 3 biomarkers",
                        "requirement": {
                            "requirement_type": "testing",
                            "expected_value": "tested by Viracor"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Newly diagnosed",
                        "criterion": "diagnosis status",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "newly diagnosed"
                        }
                    },
                    {
                        "exact_snippets": "Minnesota standard risk aGVHD",
                        "criterion": "Minnesota standard risk aGVHD",
                        "requirement": {
                            "requirement_type": "risk category",
                            "expected_value": "standard risk"
                        }
                    },
                    {
                        "exact_snippets": "Minnesota standard risk aGVHD",
                        "criterion": "Minnesota standard risk aGVHD",
                        "requirement": {
                            "requirement_type": "disease",
                            "expected_value": "acute graft-versus-host disease (aGVHD)"
                        }
                    },
                    {
                        "exact_snippets": "Ann Arbor 3 biomarkers tested by Viracor",
                        "criterion": "Ann Arbor 3 biomarkers",
                        "requirement": {
                            "requirement_type": "testing",
                            "expected_value": "tested by Viracor"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 12 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 12 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 12 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "HCT recipients over 12 years of age within the first 7 days of initial treatment of high-risk aGVHD, defined as:",
                "criterions": [
                    {
                        "exact_snippets": "HCT recipients",
                        "criterion": "HCT recipient status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "over 12 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "within the first 7 days of initial treatment of high-risk aGVHD",
                        "criterion": "time since initial treatment of high-risk aGVHD",
                        "requirement": {
                            "requirement_type": "time since initial treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "HCT recipients",
                        "criterion": "HCT recipient status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "over 12 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "within the first 7 days of initial treatment of high-risk aGVHD",
                        "criterion": "time since initial treatment of high-risk aGVHD",
                        "requirement": {
                            "requirement_type": "time since initial treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Unwilling or unable to stop GnRH antagonists, aromatase inhibitors, or anti-androgens",
                "criterions": [
                    {
                        "exact_snippets": "Unwilling or unable to stop GnRH antagonists, aromatase inhibitors, or anti-androgens",
                        "criterion": "use of GnRH antagonists, aromatase inhibitors, or anti-androgens",
                        "requirement": {
                            "requirement_type": "willingness or ability to stop",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Unwilling or unable to stop GnRH antagonists, aromatase inhibitors, or anti-androgens",
                    "criterion": "use of GnRH antagonists, aromatase inhibitors, or anti-androgens",
                    "requirement": {
                        "requirement_type": "willingness or ability to stop",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation status",
                "criterions": [
                    {
                        "exact_snippets": "Active or recent (within prior 3 months) thrombus",
                        "criterion": "thrombus",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active or recent (within prior 3 months) thrombus",
                        "criterion": "thrombus",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Active or recent (within prior 3 months) thrombus",
                        "criterion": "thrombus",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active or recent (within prior 3 months) thrombus",
                        "criterion": "thrombus",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)",
                "criterions": [
                    {
                        "exact_snippets": "Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)",
                        "criterion": "supplemental sex hormone therapy",
                        "requirement": {
                            "requirement_type": "willingness/ability to stop",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)",
                    "criterion": "supplemental sex hormone therapy",
                    "requirement": {
                        "requirement_type": "willingness/ability to stop",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Pregnancy",
                "criterions": [
                    {
                        "exact_snippets": "Pregnancy",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Women or men of childbearing potential unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment",
                "criterions": [
                    {
                        "exact_snippets": "Women or men of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment",
                        "criterion": "willingness to take precautions to avoid unintended pregnancy",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment",
                        "criterion": "willingness to take precautions to avoid unintended pregnancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "from the start of protocol treatment through 30 days after the last treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Women or men of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment",
                                    "criterion": "willingness to take precautions to avoid unintended pregnancy",
                                    "requirement": {
                                        "requirement_type": "willingness",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment",
                                    "criterion": "willingness to take precautions to avoid unintended pregnancy",
                                    "requirement": {
                                        "requirement_type": "duration",
                                        "expected_value": "from the start of protocol treatment through 30 days after the last treatment"
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of a hormone responsive malignancy",
                "criterions": [
                    {
                        "exact_snippets": "History of a hormone responsive malignancy",
                        "criterion": "hormone responsive malignancy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of a hormone responsive malignancy",
                    "criterion": "hormone responsive malignancy",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Progressive malignancy",
                "criterions": [
                    {
                        "exact_snippets": "Progressive malignancy",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Progressive malignancy",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment",
                        "criterion": "infection status (bacterial, fungal, parasitic, or viral)",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment",
                        "criterion": "infection status (bacterial, fungal, parasitic, or viral)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at initiation of protocol treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment",
                        "criterion": "infection status (bacterial, fungal, parasitic, or viral)",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment",
                        "criterion": "infection status (bacterial, fungal, parasitic, or viral)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at initiation of protocol treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Current thromboembolic disease requiring full-dose anticoagulation - patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible",
                "criterions": [
                    {
                        "exact_snippets": "Current thromboembolic disease requiring full-dose anticoagulation",
                        "criterion": "thromboembolic disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current thromboembolic disease requiring full-dose anticoagulation",
                        "criterion": "thromboembolic disease",
                        "requirement": {
                            "requirement_type": "anticoagulation dose",
                            "expected_value": "full-dose"
                        }
                    },
                    {
                        "exact_snippets": "patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible",
                        "criterion": "pharmacologic prophylaxis for thromboembolic disease",
                        "requirement": {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Current thromboembolic disease requiring full-dose anticoagulation",
                                "criterion": "thromboembolic disease",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Current thromboembolic disease requiring full-dose anticoagulation",
                                "criterion": "thromboembolic disease",
                                "requirement": {
                                    "requirement_type": "anticoagulation dose",
                                    "expected_value": "full-dose"
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible",
                            "criterion": "pharmacologic prophylaxis for thromboembolic disease",
                            "requirement": {
                                "requirement_type": "receiving",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds).",
                "criterions": [
                    {
                        "exact_snippets": "Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds)",
                        "criterion": "consent",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "voluntary",
                                "written"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds)",
                        "criterion": "consent",
                        "requirement": {
                            "requirement_type": "provider",
                            "expected_value": [
                                "adult",
                                "parent/guardian with minor assent for 12 through 17-year-olds"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Cardiac: Left ventricular ejection fraction (LVEF) ≥ 35%",
                "criterions": [
                    {
                        "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥ 35%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Left ventricular ejection fraction (LVEF) \u001e= 35%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Newly diagnosed Minnesota standard risk aGVHD with plasma amphiregulin ≥ 33 pg/ml tested at the UMN Cytokine Reference Lab. For amphiregulin lab ordering information, see Fairview Lab Guide: http://labguide.fairview.org/showtest.asp?testid=6766&format=long -OR-",
                "criterions": [
                    {
                        "exact_snippets": "Newly diagnosed Minnesota standard risk aGVHD",
                        "criterion": "Minnesota standard risk aGVHD",
                        "requirement": {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    },
                    {
                        "exact_snippets": "plasma amphiregulin ≥ 33 pg/ml tested at the UMN Cytokine Reference Lab",
                        "criterion": "plasma amphiregulin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 33,
                                "unit": "pg/ml"
                            }
                        }
                    },
                    {
                        "exact_snippets": "plasma amphiregulin ≥ 33 pg/ml tested at the UMN Cytokine Reference Lab",
                        "criterion": "plasma amphiregulin",
                        "requirement": {
                            "requirement_type": "testing location",
                            "expected_value": "UMN Cytokine Reference Lab"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Newly diagnosed Minnesota standard risk aGVHD",
                        "criterion": "Minnesota standard risk aGVHD",
                        "requirement": {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "plasma amphiregulin \u001e= 33 pg/ml tested at the UMN Cytokine Reference Lab",
                                "criterion": "plasma amphiregulin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 33,
                                        "unit": "pg/ml"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "plasma amphiregulin \u001e= 33 pg/ml tested at the UMN Cytokine Reference Lab",
                                "criterion": "plasma amphiregulin",
                                "requirement": {
                                    "requirement_type": "testing location",
                                    "expected_value": "UMN Cytokine Reference Lab"
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}